# Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

> **NCT06651281** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1380 (estimated)

## Conditions studied

- Crohn Disease
- Colitis, Ulcerative

## Interventions

- **DRUG:** Tulisokibart
- **DRUG:** Placebo to tulisokibart

## Key facts

- **NCT ID:** NCT06651281
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-25
- **Primary completion:** 2037-12-17
- **Final completion:** 2037-12-17
- **Target enrollment:** 1380 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06651281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06651281, "Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06651281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*